CURRICULUM VITAE

Joaquin Hechavarria, M.D., MSc, MSc. OH, C.G.P., CMA

(Joaquin Humberto Hechavarria Miyares)

Offices

JDH Medical Group, LLC

***** ** *** ** ***** 210

Miami, FL 33186

Phone: 305-***-****

Fax: 786-***-****

E-mail/Internet address: actb6c@r.postjobfree.com/www.jdhmedgroup.com

BACKGROUND:

Education and Training

Postgraduate

2003-2004 Postdoctoral fellowship

Occupational Health Division

Mapfre Medicine Foundation

Madrid, Spain

2003 Subspecialty fellowship (Occupational Medicine)

Occupational Health Institute

Medical Sciences Institute

Havana, Cuba

1995-1997 Subspecialty fellowship (Pulmonary Diseases)

Department of Medicine

Medical Sciences Institute

Havana, Cuba

1994-1995 Residency (Internal Medicine)

Department of Medicine

Medical Sciences Institute

Santiago de Cuba, Cuba

1993-1994 Internship (Internal Medicine)

Department of Medicine

Medical Sciences Institute

Santiago de Cuba, Cuba

Undergraduate/Graduate

2010-2013 Doctoral Degree in Healthcare Education/Gerontology

Nova Southeastern University

Davie, Ft Lauderdale, FL, USA

2013 Credentialed Professional Gerontologist

National Association for Professional Gerontologists

Healdsburg, CA

2008-2010 Master Degree in Science

Nova Southeastern University

Davie, Ft Lauderdale, FL, USA

1999-2000 Master Degree in Occupational Health

Institute of Occupational Health

Department of Medicine

Medical Sciences Institute

Havana, Cuba

1994 M.D. degree (Honors Class)

Medical Sciences Institute

Santiago de Cuba, Cuba

Secondary Education

1985-1987 U.S. High School Diploma (Honors)

IPVCE “Antonio Maceo”

Santiago de Cuba, Cuba

Medical Licenses/Other Licenses

2004-Present

Medical Doctor, Health Department of Bogota, Colombia.

2008-Present

Certified Medical Assistant, Miami, FL, USA (Certification number: 107308)

1994-2003

Medical Doctor, Ministry of Public Health, Havana, Cuba (License number: 67733)

Honors and Awards

2013

Student of the Year (Doctoral). Nova Southeastern University.

Davie, FL, USA.

2012

HEPEG Award Leadership. Nova Southeastern University.

Davie, FL, USA.

2002

Investigator Award (Occupational Health). Occupational Health Institute.

Havana, Cuba

2001

Investigator Award (Occupational Health). Occupational Health Institute.

Havana, Cuba

2000

Investigator Award (Occupational Health). Occupational Health Institute.

Havana, Cuba

1999

Investigator Award (Occupational Health). Occupational Health Institute.

Havana, Cuba

1997

Award for Excellent Academic Results (Subspecialty fellowship: Pulmonary Diseases). Medical Sciences Institute

Havana, Cuba

1996

Award for Excellent Academic Results (Subspecialty fellowship: Pulmonary Diseases). Medical Sciences Institute

Havana, Cuba

1995

Award for Excellent Academic Results (Subspecialty fellowship: Pulmonary Diseases). Medical Sciences Institute

Havana, Cuba

1994

Award Honors Class. Medical Sciences Institute

Santiago, Cuba

Academic Appointments

2009-Present

Professor (with tenure). Health Sciences. Ana G. Mendez University.

Miramar, FL, USA.

2013-Present

Regular Member of IRB. Ana G. Mendez University.

Miramar, FL, USA

2010-2012

Professor (with tenure). Health Department. FastTrain College.

Miami, FL, USA

2008-2011

Adjunct Professor. Health Sciences. Department. City College.

Miami, FL, USA.

1999-2003

Clinical Associate Professor of Medicine (clinical faculty). Medical Sciences Institute.

Havana, Cuba.

1999-2003

Clinical Associate Professor (clinical faculty). Department of Occupational Medicine. Medical Sciences Institute.

Havana, Cuba.

2002

Adjunct Professor (non-tenure track). Faculty of Social Communication. Havana University.

Havana, Cuba.

Professional/Administrative Experience

06/2014-Present

Research Director/Sub-Investigator. JDH Medical Group, LLC-Miami, FL, USA.

2011-05/2014

Sub-Investigator. School of Clinical Research-Miami, FL, USA

2010-2012

Research Director. School of Clinical Research-Miami, FL, USA

2010-2012

Director of Quality Assurance. School of Clinical Research-Miami, FL, USA

2010-Present

Member of the Allied Health Advisory Council of City College-Miami, FL,

USA

2008-2010

Lead Coordinator/Senior CRC. Suncoast Research Group-Miami, FL, USA

2008-2009

Site Manager/Senior Clinical Research Coordinator. Community Research-Miami, FL, USA

2004-2007

Scientific Director/Principal Investigator. CORBANCA Foundation-Bogota, D.C., Colombia

1999-2003

Director of Department of Occupational Pulmonology. Occupational Health Institute-Havana, Cuba

1994-1998

Specialist of the Division of Pulmonology. Benefico-Juridico Hospital-Havana, Cuba

RESEARCH EXPERIENCE

Principal Investigator (Havana, Cuba):

1.Chronic Obstructive Pulmonary Disease in workers exposed to dusts. 1998.

2.Establishment of spirometric values in Cuban population. 1999.

3.Obstructive Apnea's s syndrome in professional drivers. 2000.

4.Bacterial resistance in Tuberculosis. 1999.

5.Sensitivity to chromium in workers with Contact dermatitis. 2001.

6.Sensitivity to nickel in workers with Contact dermatitis. 2001.

7.Prevalence of occupational asthma in Cuba. 2001.

8.Evaluation of the quality of the spirometric measurements in the Lung Function Laboratory in the period 1980-2000. 2001.

9.Prevalence of chronic bronchitis in the Cuban population. 2001.

10.Design curriculum of specialization in Pneumology in Cuba. 2003.

11.Development of the Program of the Masters in Occupational Health. 2001.

12.Development of the National Program of Asthma. 2002.

13.Participatory methods in Pedagogy. 2002.

14.Pneumonia in elderly patients. 1998.

15.Asthma and pregnancy. 2002.

16.Evaluations of the lung function in patients with sicklemia. 2001.

17.Validation of a Chronic Obstructive Pulmonary Disease screening questionnaire for Cuban population.

Lead/Senior Clinical Research Coordinator (Miami, Florida, USA):

18.A phase II, double-blind randomized, placebo-controlled, parallel group, multicenter study to evaluate daily treatment with SYR-472 in subjects with type 2 Diabetes.

19.A phase IIIB, double-blind randomized study to determine the efficacy and safety of Pioglitazone HCL and Metformin HCL fixed dose combination therapy compared to Pioglitazone HCL monotherapy to metformin HCL monotherapy in the treatment of subjects with type 2 Diabetes.

20.A Randomized, Double-Blind, Multicenter, Placebo-controlled, Phase III Superiority Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, versus Placebo Ointment Applied Twice Daily for 5 days in the Treatment of Adult and Pediatric Subjects with Secondarily-Infected Traumatic Lesions.

21.A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy and Safety Of Donepezil Hydrochloride (Aricept ®) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome.

22.A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Study Drug to Active Comparator, Both Active Treatments to a Vehicle Control in the Treatment of Atopic Dermatitis.

23.A Phase II, Double Blind, Placebo-controlled, Randomized, Multi-Center, Parallel Group Study to Evaluate The Efficacy and Safety of T89 in Patients with Chronic Stable Angina Pectoris.

24.Protocol CS8635-A-U301: A randomized, Double-Blind, Paralell Group Study Evaluating the Efficacy and Safety of Co-Administration of a Triple Combination Therapy of Olmesartan Medoxomil, Amlodipine Besylate, and Hydrochlorothiazide in Subjects with Hypertension (Daiichi Sankyo Pharma Development).

25.Protocol: MONVISC-0702: A randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-linked Sodium Hyaluronate to Provide Symptomatic Relief of Osteoarthritis of the Knee.

26.Protocol SYR-322-303: A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Subjects with Type 2 Diabetes.

27.Protocol 018-00: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium.

28.Protocol 035: A Sub-Study to Explore Biomarkers of Physical Function in the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated with Vitamin D and Calcium.

29.MK0974-049: A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of MK-0974 for Migraine Prophylaxis in Patients With Episodic Migraine

30.GLP 112753: A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When used in Combination With Metformin Compared with Metformin Plus Sitagliptin, Metformin Plus Glimepiride, and Metformin Plus Placebo in Subjects With Type 2 Diabetes Mellitus

31.GLP 112754: A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Long Term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes Mellitus.

32.GLP 112755: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Pioglitazone With or Without Metformin in Subjects with Type 2 Diabetes Mellitus.

33.GLP 112757: A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide Administered in Combination With Metformin and Glimepiride Compared With Metformin Plus Glimepiride and Placebo and With Metformin Plus Glimepiride and Pioglitazone in Subjects With Type 2 Diabetes Mellitus

34.Protocol ID: NEB-MD-11: A Randomized, Double-Blind, Placebo-Controlled Study of The Efficacy And Safety of Nebivolol Added to Antihypertensive Treatment With Lisinopril Or Losartan In Patients With Hypertension

35.Protocol 007: A Worldwide, Multicenter, Double Blind, Randomized, Placebo Controlled, Dose Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of MK 0736 When Added to Ongoing Therapy With Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) in Patients With Diabetes and Hypertension.

36.E3810-A001-307: A Multicenter Randomized Double-Blind Study to Compare the Efficacy, Safety and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD).

37.E3810-A001-308: A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

38.Protocol Number E3810-G000-302: Validation of patient reported outcome measures for the assessment of GERD symptoms and their subsequent impact on patients with a partial response to PPI treatment in a two part multi-center phase IIA study including a four week randomised, double-blind, placebo-controlled parallel-group treatment phase with AZD3355, 65 mg bid as add-on treatment to a PPI.

39.MK-0431 PN102-01: A Multicenter, Randomized, Double-Blind Study of the Co-Administration of Sitagliptin and Pioglitazone in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control MK-0431 PN 102-01

40.A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Patients With Type 2 Diabetes Mellitus.

Sub-Investigator (Miami, Florida, USA):

41.Johnson&Johnson R331333PAI3025 (Low Back Pain)

42.Merck 3207-009 (Acute Migraine)

43.Johnson&Johnson 27018966IBS2001 (Irritable Bowel Syndrome)

44.Merck 0859-019 (Hypercholesterolemia)

45.Merck 0431A-066 (Type II Diabetes)

46.Merck 0974-065 (Menstrual Migraine)

47.Merck 0524-102 (Cholesterol)

48.NovoNordisk 1250-3580 (Type II Diabetes)

49.NovoNordisk 5401-3590 (Type II Diabetes)

50.NovoNordisk 5401-3726 (Type II Diabetes)

51.NovoNordisk 22155B (Flu H1N1)

52.A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy.

53.A Phase I, Open-Label, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of V212/Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults with Hematologic Malignancies Receiving Treatment with Anti-CD20 Monoclonal Antibodies.

54.A Phase II Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Immunogenicity of V212 in Adult Patients with Autoimmune Disease. (MERCK)

55.A Multicenter, Randomized, Double-Blind Clinical Trial to Assess the Efficacy and Safety of Ciprofloxacin 0.3% plus Fluocinolone Acetonide 0.025% Otic Solution Compared to Ciprofloxacin 0.3% Otic solution and to Fluocinolone Acetonide 0.025% Otic Solution in the Treatment of Acute Otitis Media with Tympanostomy Tubes (AOMT) in Pediatric Patients.

56.REVEAL (Randomized EValuation of the Effects of Anacetrapib through Lipid-modification): A large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease.

57.Prospective Randomized Evaluation of Celecoxib Integrated Safety vs. Ibuprofen Or Naproxen.

58.A phase III randomized, double-blind, parallel group study to evaluate the efficacy and safety of once daily oral administration of BI 10773 25 mg/linagliptin 5 mg and BI 10773

59.10 mg/linagliptin 5 mg Fixed Dose Combination tablets compared with the individual components (BI 10773 25 mg, BI 10773 10 mg, and linagliptin 5 mg) for 52 weeks in treatment naïve and metformin treated patients with type 2 diabetes mellitus with insufficient glycaemic control.

60.An Efficacy and Safety Trial of SCH 900931 in Subjects with Mild to Moderate Alzheimer’s disease.

61.6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® in Insulin-Naïve Patients with Type 2 Diabetes Mellitus not Adequately Controlled with Oral Antihyperglycemic Drugs with a 6-month Comparative Extension Period (Sanofi)

62.6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected in the Morning or Evening in Patients with Type 1 Diabetes Mellitus with a 6-month Safety Extension Period (Sanofi)

63.Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients with Atrial Fibrillation (phase II/III) (Boehringer Ingelheim)

Research Trainings:

1.International Conference on Harmonization

2.FDA Regulated Research and ICH

3.Investigator Obligations in FDA-Regulated Clinical Research

4.Monitoring of Clinical Trials by Industry Sponsors

5.Managing Investigational Agents According to GCP Requirements

6.Conducting Clinical Trials of Medical Devices

7.Detection and Evaluation of Adverse Events

8.Reporting Serious Adverse Events

9.Informed Consent Process and Forms.

10.HIPAA regulations and clinical trials.

11.Collaborative IRB Training Initiative (CITI)

12.IATA Training

13.HIPAA Certification

Publications (Peer-reviewed Journals and Reports):

1.Occupational asthma. Current considerations. Med Journal, No. 3, 1999.

2.Chronic Bronchitis Mortality in Cuba. 1987-1997. Biomedical Journal, No. April, 1999.

3.Exposure to B. Bassiana in the Cree workers. Occupational Health J, Vol 1, No. 1, 1999.

4.Dysfunction syndrome of reactive airways. Current considerations. Occupational Health J, Vol 1, No. 1, 1999.

5.Use of inhaled furosemide in asthma. Occupational Health J, Vol 1, No. 2, 2000.

6.Lung cancer. Ethical considerations. Occupational Health J, Vol 1, No. 2, 2000.

7.Informed consent. Clinical considerations. Occupational Health J, Vol 1, No. 2, 2000.

8.National Program of Master Degree in Occupational Health. Occupational Medicine Institute. Approved by the Ministry of Higher Education.

9.National Program of Master Degree in Environmental Health. National Institute of Hygiene and Epidemiology. Approved by the Ministry of Higher Education. 2001

10.Community-acquired pneumonia. Med Act. Ameijeiras Hospital. 2001. Specialty Series

11.Pulmonary eosinophilia. General considerations. Journal of Medicine. Vol 40, No. 4, 2001.

12.Skin cancer and occupation. Journal of Medicine. Vol 40, No. 4. 2001.

13.Perceived risk of skin cancer from sun exposure. Occupational Med. Vol 10, No. 1, 2002. Special Edition.

14.Establishment of the regression equations for the calculation of the normal ventilatory function in the working population of Puerto Padre. Las Tunas. Occupational Med. Vol 9, No. 2, 2002.

15.National Program for Control of Asthma. National Asthma Commission. Vice Ministry of Hygiene and Epidemiology. 2002.

16.Participatory methods in education. Occupational Med. Vol 10, 2002 Special Edition.

17.Evaluation of the curriculum design in Master of Occupational Health Program. Occupational Med. Vol 11, No. 1, 2003.

18.Textbook of Occupational Medicine. ECOPETROL, Colombia. 2000.

19.Manual of Occupational Diseases. Occupational Medicine Institute. INSAT. 2003.

20.Stress and skin manifestations. Indexmedico Journal. Issue 5, 2003. (Electronic publication) journal/edicion5/stress http://indexmedico.com/publicaciones/indexmed skin / rodriguez garcia.htm.

21.The tutor and educational communicator. Indexmedico Journal. Issue 5, 2003. http://indexmedico.com (electronic publication).

22.The use of educational facilities in the educational process. Indexmedico Journal. Issue 5, 2003. http://indexmedico.com (electronic publication).

23.Occupational Nursing in Cuba: Challenges in the new millennium. Indexmedico Journal. Seventh Edition, 2003. (Electronic publication) (Author).

Grant and Contract Awards:

2003 MAPFRE Foundation. Research Fellowship Occupational Medicine

(MAPFRE Medicine). National Silicosis Institute. Oviedo, Spain. € 7,500.00

2004 MAPFRE Foundation. Research Fellowship Occupational Medicine

(Larramendi 2004). National Silicosis Institute. Oviedo, Spain.

Establishment of a monitoring system for the diagnosis, prevention, and

control of occupational respiratory diseases in Cuba. € 15,000

Selected Presentations (lead author or presenter only):

Undergraduate:

1.Behavior of urea and creatinine concentrations in serum of pregnant women with elevated alpha-fetoprotein. Medical Sciences Institute. Santiago de Cuba, Cuba. Student Scientific Meeting. Date: May 27, 1989. Results: Award.

2.Philosophical Considerations about the evolution of the concept of medical error through social historical development in our country. Medical Sciences Institute. Santiago de Cuba, Cuba. Student Scientific Meeting. Date: March 27, 1989. Results: Award.

3.Behavior of the concentration of serum uric acid levels of pregnant women with elevated alpha-fetoprotein. Date: May 27, 1989. Medical Sciences Institute. Santiago de Cuba, Cuba. Student Scientific Meeting. Results: Award. A General consideration about the influence of physical exercise in reducing the risk of the onset of MI. Date: April 28, 1990. Medical Sciences Institute. Santiago de Cuba, Cuba. Student Scientific Meeting. Results: Mention.

4.Comparative aspects of the microscopic structure of the heart in the early stages of birth in rats. Date: April 28, 1990. Medical Sciences Institute. Santiago de Cuba, Cuba. Student Scientific Meeting. Results: Best Research.

5.General considerations about the formation of personality in the group and its relationship with the practitioner. Date: April 28 to May 1991.Medical Sciences Institute. Santiago de Cuba, Cuba. Student Scientific Meeting. Results: Award.

6.Sexual dysfunction. General Considerations. Date: May 5, 1991. Medical Sciences Institute. Santiago de Cuba, Cuba. Student Scientific Meeting. Results: Award.

7.Philosophical premise for the emergence and development of Toxicology in Cuba. Date: May 25, 1991. Medical Sciences Institute. Santiago de Cuba, Cuba. Student Scientific Meeting. Results: Mention.

8.Treatment of pseudoarthrosis with the use of magnet therapy. Date: May 25, 1991. Medical Sciences Institute. Santiago de Cuba, Cuba. Student Scientific Meeting. Results: Mention.

9.Analysis of mortality by MI in patients treated in ICU of Cardiology "Saturnino Lora” Hospital. Date: May 25, 1991. Medical Sciences Institute. Santiago de Cuba, Cuba. Student Scientific Meeting. Results: Award.

10.Congenital heart disease at Children's North Hospital during 1989-1990. Date: May 25, 1991. Medical Sciences Institute. Santiago de Cuba, Cuba. Student Scientific Meeting. Results: Mention.

11.Incidence of Spine Injuries in Orthopedics and Neurosurgery services at "Saturnino Lora" Hospital during the period 1987-1991. Date: April 25, 1992. Medical Sciences Institute. Santiago de Cuba, Cuba. Student Scientific Meeting. Results: Mention.

12.Determination of ASA in the urine of Winstar rats by chromatography. Date: April 25, 1992. Medical Sciences Institute. Santiago de Cuba, Cuba. Student Scientific Meeting.

13.Congenital Cardiopathies: Considerations. Date: April 25, 1992. Medical Sciences Institute. Santiago de Cuba, Cuba. Student Scientific Meeting.

14.Relationship between the level of information of the population and sexually transmitted diseases. Date: April 25, 1992. Medical Sciences Institute. Santiago de Cuba, Cuba. Student Scientific Meeting.

15.Factors and evolution of neonates with sepsis potential. Date: April 22, 1992. Medical Sciences Institute. Santiago de Cuba, Cuba. Student Scientific Meeting. Results: Award.

16.Multiple Endocrine Tumors. Presentation of a case. Date: April 30, 1993. Medical Sciences Institute. Santiago de Cuba, Cuba. Student Scientific Meeting. Results: Mention.

17.Results of Percutaneous discectomy in lumbar disc herniation. Date: April 30, 1993. Medical Sciences Institute. Santiago de Cuba, Cuba. Results: Award.

18.Ankylosing spondylitis. Presentation of a case. Date: April 30, 1993. Medical Sciences Institute. Santiago de Cuba, Cuba. Student Scientific Meeting.

19.Electromagnetic field effects pseudarthrosis of the tibial shaft. Date: April 30, 1993. Medical Sciences Institute. Santiago de Cuba, Cuba. Student Scientific Meeting.

20.Results of the Luque technique in trauma spinal cord injuries. Date: April 30, 1993. Medical Sciences Institute. Santiago de Cuba, Cuba. Student Scientific Meeting.

21.Digital elongation with external minifixators. Date: April 30, 1993. Medical Sciences Institute. Santiago de Cuba, Cuba. Student Scientific Meeting.

22.Some considerations about Transculturation. Date: 1993. Medical Sciences Institute. Santiago de Cuba, Cuba.

23.Clinical Discussion in the Department of Respiratory Diseases. Date: June 20, 1992. Medical Sciences Institute. Santiago de Cuba, Cuba.

Postgraduate

1.Incidence of Spine Injuries in Orthopedics and Neurosurgery services at "Saturnino Lora" Hospital during the period 1987-1991. Date: April 25, 1992. Medical Sciences Institute. Santiago de Cuba, Cuba. Scientific Meeting at Joaquin Castillo Duany Hospital. Results: Award.

2.Results of Percutaneous discectomy in lumbar disc herniation. Date: April 30, 1993. Medical Sciences Institute. Scientific Meeting at Joaquin Castillo Duany Hospital. Santiago de Cuba, Cuba. Results: Award.

3.Behavior of enzyme markers and hepatitis B. Study in patients undergoing plasmapheresis regimen and treatment with interferon. Date: April 27, 1995. Medical Faculty # 2 Santiago de Cuba, Cuba. Student Scientific Meeting. Results: Mention.

4.Smoking: Causes of habituation and addiction. Date: April 27, 1995. Faculty of Medicine No. 2. Santiago de Cuba. Cuba. Student Scientific Meeting. Results: First Place.

5.Use of furosemide in bronchial asthma. Date: December 22, 1995. Faculty "Salvador Allende". Havana. Integrated Scientific Meeting.

6.Pulmonary tuberculosis in Cuba and the world. Date December 22, 1995. Faculty "Salvador Allende", Havana City. Integrated Scientific Meeting. Results: selected Institute Forum.

7.5 mg Intal aerosol: Multicenter study the effectiveness of treatment. Date: December 22, 1995. Faculty "Salvador Allende", Havana City. Integrated Scientific Meeting. First National Congress of Pneumology.

8.Tuberculosis and AIDS in Cuba. Date: December 22, 1995. Faculty "Salvador Allende". Havana, Cuba. Integrated Scientific Meeting. Salvador Allende Hospital.

9.Pneumonia. Study of four months. Date: May 17, 1996. "Salvador Allende" Hospital. Havana, Cuba. IX Scientific Meeting. First National Congress of Pneumology.

10.Habituation and dishabituation in smokers over 60 years. Date: May 9, 1996. II Central American and Caribbean III National Congress, First Meeting of the Southern Cone to the Caribbean, IV Elderly Care Seminar. First Meeting of Cuban-Brazilian. First National Congress of Pneumology.

11.Percutaneous discectomy in lumbar disc herniation in patients over 50 years. May 9, 1996. II Central American and Caribbean III National Congress, First Meeting of the Southern Cone to the Caribbean, IV Elderly Care Seminar. First Meeting of Cuban-Brazilian. First National Congress of Pneumology.

12.Pneumonia in the elderly. Multicenter study. Date: November 22, 1996. "Frank País" Hospital. IV National Congress of Hygiene and Epidemiology. First National Congress on Infectious Diseases.

13.Difficulties in the diagnostic of Tuberculosis: Presentation of a case. Date: March 7, 1997. V Latin American Congress on Tropical Medicine. Cuban Congress of Microbiology.

14.Behavior of extrapulmonary tuberculosis in respiratory medicine. Benefico-Juridico Hospital. Date: March 7, 1997. Latin American Congress on Tropical Medicine. Cuban Congress of Microbiology.

15.Childhood Tuberculosis. Current approaches. Date: December, 1996. Pediatric Hospital. Scientific Meeting.

16.Clinical comparison of two spirometers. Date: February 7-8, 1997. Faculty "Salvador Allende" Havana, Cuba. Integrated Scientific Meeting.

17.Ventilatory function tests in patients exposed to asbestos. Date: February 7-8, 1997. Faculty "Salvador Allende". Havana, Cuba. Integrated Scientific Meeting.

18.Ventilatory function tests: differences between sexes. Date: February 7-8, 1997. Havana, Cuba. First National Congress of Pneumology.

19.Informed consent and its application in patients with lung malignancies. Date: March 29, 1997. First National Congress of Pneumology. Villa Clara, Cuba. Arnaldo Milian Castro Hospital.

20.Changes in ventilatory function tests during the menstrual cycle. Date: March 29, 1997. First National Congress of Pneumology. Villa Clara, Cuba. Arnaldo Milian Castro Hospital.

21.Pulmonary complications of gastroesophageal reflux. Date: March 29, 1997. First National Congress of Pneumology. Villa Clara, Cuba. Arnaldo Milian Castro Hospital.

22.Clinical implications of Pseudomonas aeruginosa in sputum. Date: March 29, 1997. First National Congress of Pneumology. Villa Clara, Cuba. Arnaldo Milian Castro Hospital.

23.Endoscopy in the elderly. Date: March 29, 1997. First National Congress of Pneumology. Villa Clara, Cuba. Arnaldo Milian Castro Hospital.

24.Pharmacotherapy in bronchial asthma. Date: March 29, 1997. First National Congress of Pneumology. Villa Clara, Cuba. Arnaldo Milian Castro Hospital.

25.Pulmonary Endometriosis: Report of two cases. Date: March 29, 1997. First National Congress of Pneumology. Villa Clara, Cuba. Arnaldo Milian Castro Hospital.

26.Small cell lung carcinoma: statistical behavior in the years 1993-1994 in the Benefico-Juridico Hospital. Date: March 29, 1997. Villa Clara, Cuba. First National Congress of Pneumology. Arnaldo Milian Castro Hospital.

27.Pulmonary Tuberculosis in the elderly: A five-year study. Date: March 29, 1997. First National Congress of Pneumology. Villa Clara, Cuba. Arnaldo Milian Castro Hospital.

28.Obstructive Pulmonary Disease in workers exposed to dusts. Date: April 17, 1998. CIMEQ Hospital. Havana, Cuba. Congress of the Caribbean Medical Association (AMECA 98).

29.Use of inhaled furosemide on bronchial asthma. Date: April 17, 1998. CIMEQ Hospital. Havana, Cuba. Congress of the Caribbean Medical Association (AMECA 98).

30.Occupational Asthma in workers of the Pharmaceutical Industry. Date: April 17, 1998. CIMEQ Hospital. Havana, Cuba. Congress of the Caribbean Medical Association (AMECA 98).

31.Conference on Occupational Asthma. Date: September, 1999. Havana, Cuba. Cuba-Spain Meeting of Asthma.

32.Conference Asthma and Prevention of Occupational hypersensitivity pneumonitis. Date: July 2000. Havana, Cuba. Second Congress of Pneumology.

33.Nicotine replacement therapy combined for smoking cessation. Date: October, 2000. II International Symposium “Health and Labor” and AMECA Congress. Havana, Cuba.

34.Smoking in the health professionals. Date: October, 2000. II International Symposium “Health and Labor “and AMECA Congress.

35.Preventive medical examinations in Occupational Medicine: some considerations about specific risks. Date: July, 1999. II International Symposium “Health and Labor”.

36.Establishment of normal ventilatory function values in the Cuban population. Date: July, 1999. II International Symposium “Health and Labor”.

37.An alert in workers exposed to dust. Date: July, 1999. II International Symposium “Health and Labor”.

38.Epidemiological aspects of work-related diseases. Date: July, 1999. II International Symposium “Health and Labor”.

39.Detection of Obstructive Sleep Apnea Syndrome Sleep professional drivers. Date: July, 1999. II International Symposium “Health and Labor”.

40.Bacterial resistance in tuberculosis in patients admitted to the Benefico-Juridico

Contact this candidate